Share This Author
Huntington's disease: from molecular pathogenesis to clinical treatment
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease
The peripheral immune system was examined and found widespread evidence of innate immune activation detectable in plasma throughout the course of HD, suggesting parallel central nervous system and peripheral pathogenic pathways of immune activation in HD.
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data
PINK1-Associated Parkinson's Disease Is Caused by Neuronal Vulnerability to Calcium-Induced Cell Death
Huntington disease: natural history, biomarkers and prospects for therapeutics
The natural history of HD is described, including the timing of emergence of motor, cognitive and emotional impairments, and the techniques that are used to assess these features, and potential future roles of these biomarkers in clinical trials are reviewed.
Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population.
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records
- S. Evans, I. Douglas, M. Rawlins, N. Wexler, S. Tabrizi, L. Smeeth
- MedicineJournal of Neurology Neurosurgery & Psychiatry
- 12 March 2013
The prevalence of diagnosed HD is clearly substantially higher in the UK than suggested from previous studies, including more accurate diagnoses, better and more available therapies and an improved life expectancy, even with HD.
The genetic and clinical diagnosis of the condition, its clinical assessment and the multidisciplinary management of symptoms, given the absence of effective disease-modifying therapies are described, as well as the concept of genetic modifiers of the disease.